Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.

about

Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.

Item

http://www.wikidata.org/entity/Q39028644

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Granisetron Extended-Release I ...... y-Induced Nausea and Vomiting.

@en

Granisetron Extended-Release I ...... y-Induced Nausea and Vomiting.

@nl

type

Item

label

Granisetron Extended-Release I ...... y-Induced Nausea and Vomiting.

@en

Granisetron Extended-Release I ...... y-Induced Nausea and Vomiting.

@nl

prefLabel

Granisetron Extended-Release I ...... y-Induced Nausea and Vomiting.

@en

Granisetron Extended-Release I ...... y-Induced Nausea and Vomiting.

@nl

P1476

Granisetron Extended-Release I ...... y-Induced Nausea and Vomiting.

@en

P2093

Emma D Deeks

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients

Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomiz

Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.

Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron

Transdermal granisetron.

A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation.

5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.

Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.

P2888

s40265-016-0664-2

P304

1779-1786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-016-0664-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27915445

http://www.w3.org/2001/XMLSchema#string

P921

granisetron